Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

EU green light for Novartis’ skin cancer therapy

Swiss firm’s basal cell carcinoma treatment can now be launched across Europe

- PMLiVE

FDA slams Kardashian West’s Instagram drug promotion

Morning-sickness drug firm Duchesnay criticised over social media marketing

- PMLiVE

FDA grants priority review for new Keytruda licence

Merck’s PD-1 drug being assessed for first-line melanoma patients

- PMLiVE

Novartis licenses cancer support drug from Aveo Oncology

Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

Sanofi reception

Sanofi and Evotec to work together on diabetes and cancer

Willfocus on beta cell-modulating diabetes treatments and immuno-oncology therapies

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

- PMLiVE

FDA approves world’s first 3D printed drug

Aprecia’s epilepsy treatment Spritam seen as the future of drug manufacturing

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

Sanofi reception

Sanofi and Regeneron extend partnership to cancer

Sanofi will pay more than $2bn to the firm for immunotherapy research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links